Hybrid PET/MRI for heart amyloidosis imaging
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study uses a hybrid PET/MRI scanner to take detailed images of the heart in people with amyloidosis. The goal is to see how well this scan shows the buildup of amyloid protein, which could help doctors better diagnose and manage the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 40 years old
- You have been diagnosed with amyloidosis (either the ATTR or AL type)
- You have not yet started any treatment for amyloidosis
- You are not pregnant (or have a negative pregnancy test before imaging)
- You do not have any MRI safety issues, such as very poor kidney function, contrast allergy, or unsafe metal implants
- You can give your consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan tracer to see how consistent the images are in people with heart amyloidosis (a buildup of abnormal protein in the heart) and in people without the condition. The goal is to improve diagnosis and monitoring.
This study tests a new PET imaging agent that may help doctors see amyloid buildup in the heart more clearly. It may help people with heart amyloidosis or those suspected of having it.
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
This study uses two types of imaging (PET/CT and MRI) to see if they can better predict outcomes for people with AL cardiac amyloidosis. The goal is to improve how doctors understand and manage the disease.
This study uses a new imaging technique (PET scan with a tracer called evuzamitide) to detect a type of heart disease called cardiac amyloidosis in patients whose standard heart scans were unclear but who have elevated levels of a new blood marker (TAD1). The goal is to find a better way to diagnose this condition.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.